ライフサイエンスコーパス: VMA

1 VMA was present in 101 (25.1%) eyes with exudative AMD,

2 s were +4.7 (PVD), +3.2 (RELEASE), and -0.2 (VMA) in the quarterly regimen and +4.9 (PVD), +12.7 (REL

3 At month 6, among the 26 VMA+ eyes (at baseline), 7 eyes demonstrated PVD, 17 eye

4 of vitreomacular contact (RELEASE; n = 48), VMA (n = 37), or PVA (n = 4).

5 n and +4.9 (PVD), +12.7 (RELEASE), and +7.5 (VMA) in the monthly regimen.

6 to identify the presence (VMA+) or absence (VMA-) of VMA.

7 A greater proportion of patients achieved VMA resolution and total PVD at month 12 with ocriplasmi

8 in ocriplasmin-treated patients who achieved VMA resolution at day 28.

9 ated and resulted in more patients achieving VMA resolution and PVD with less anti-VEGF use compared

10 -toprorenin ratio and vanillylmandelic acid (VMA) excretion (P < 0.025), tests of sympathetic nerve f

11 5(OH)2D3, and urinary vanillylmandelic acid (VMA) were measured by ELISA, and serum and urinary phosp

12 patients with focal vitreomacular adhesion (VMA) and exudative age-related macular degeneration (AMD

13 ar AMD who presented vitreomacular adhesion (VMA) detected by spectral-domain optical coherence tomog

14 ss the prevalence of vitreomacular adhesion (VMA) in consecutive naive eyes diagnosed with exudative

15 The impact of vitreomacular adhesion (VMA) resolution on patient-reported visual function in s

16 r traction (VMT) and vitreomacular adhesion (VMA), fluid, and central thickness.

17 al attachment (PVA), vitreomacular adhesion (VMA), partial vitreous detachment without vitreomacular

18 sted for presence of vitreomacular adhesion (VMA), width of vitreous adhesion (focal <1500 mum versus

19 tment of symptomatic vitreomacular adhesion (VMA)/vitreomacular traction, including full-thickness ma

20 this relationship "variance-mass allometry" (VMA).

21 rly treatment in the RELEASE (P = 0.008) and VMA (P = 0.043) groups.

22 6.67 and 6.86+/-7.58 letters in the VMA+ and VMA- groups, respectively (P = 0.007).

23 .31 and -161.84+/-131.34 mum in the VMA+ and VMA- groups, respectively (P = 0.681).

24 In eyes in the CATT, VMT and VMA were infrequent.

25 n binding in ventromedial hypothalamic area (VMA), medial basal hypothalamic area (MBA), arcuate nucl

26 At baseline, 26 patients were classified as VMA+ and 98 patients were classified as VMA-.

27 d as VMA+ and 98 patients were classified as VMA-.

28 r with SD-OCT than TD-OCT to detect baseline VMA (kappa 0.6 vs. 0.52); FTMH (kappa 0.9 vs. 0.78); and

29 ith FTMH, phakic eyes, and eyes with a focal VMA </= 1500 mum.

30 eveloped PVD were classified as having focal VMA, with the diameter of vitreous attachment ranging fr

31 atients with nonsurgical resolution of focal VMA at day 28, nonsurgical full-thickness macular hole (

32 ry subgroups without them: presence of focal VMA, presence of FTMH, absence of ERM, and phakic lens s

33 Eyes with focal VMA have a greater chance to develop PVD than eyes with

34 ent agreement was 97%, 92%, 95%, and 82% for VMA, vitreous adhesion width, FTMH, and ERM, respectivel

35 Team grading reproducibility for VMA (kappa 0.91, 95% confidence interval [CI] 0.81-1.00)

36 emonstrated PVD, 17 eyes showed no change in VMA status, and 2 eyes were not gradable and were exclud

37 Secondary end points reported included VMA release over time, total posterior vitreous detachme

38 vinyl monomers including vinyl methacrylate (VMA), allyl methacrylate (AMA), 4-vinylbenzyl methacryla

39 inyl monomers, including vinyl methacrylate (VMA), allyl methacrylate (AMA), and N,N-diallyl acrylami

40 and -136 mum (RELEASE), and -93 and -87 mum (VMA) in the monthly and quarterly regimens, respectively

41 the reader-determined presence or absence of VMA (96.7%), FTMH (97.1%), and all other baseline parame

42 NV development in the presence or absence of VMA (P = 0.0966).

43 The stage, size, and presence or absence of VMA were documented for each MH.

44 We recorded the vitreomacular angle of VMA nasally and temporally, the horizontal diameter of V

45 o develop PVD than eyes with a broad area of VMA.

46 y and temporally, the horizontal diameter of VMA, macular thickness, visual acuity, photoreceptor lay

47 cellent agreement for the study endpoints of VMA resolution (95.4%) and FTMH closure (100%) at day 28

48 line OCT features and the study endpoints of VMA resolution and FTMH closure.

49 nd the theoretically predicted parameters of VMA, using detailed data on individual oak trees (Quercu

50 Inclusion criteria included presence of VMA and best-corrected visual acuity (BCVA) of 20/32 or

51 Therefore, the presence of VMA should not preclude patients with DME from receiving

52 significant difference in the prevalence of VMA in eyes affected by AMD compared with age-matched co

53 Spontaneous release of VMA (RVMA) was found in 15 (15.3%) eyes with exudative A

54 Resolution of VMA at day 28 was achieved more often in younger patient

55 ify the presence (VMA+) or absence (VMA-) of VMA.

56 e feasible, whereas patients with RELEASE or VMA may benefit from intensive retreatment.

57 9 +/- 0.4 (P = 0.02) for eyes without VMT or VMA (n = 377).

58 ed in a lower percentage of eyes with VMT or VMA at baseline (11.7%) than with neither condition (22.

59 Eyes with VMT or VMA treated as needed required on average 2 more injecti

60 At baseline and follow-up, VMT or VMA were not associated with VA.

61 with neither (n = 972), patients with VMT or VMA were younger (mean +/- standard error, 75.5 +/- 0.6

62 aseline, 143 patient eyes (12.8%) had VMT or VMA.

63 A total of 118 eyes remained with persistent VMA.

64 In the ocriplasmin group, pharmacologic VMA resolution at day 28 was higher in subgroups with th

65 met its primary end point with pharmacologic VMA resolution at day 28 being significantly higher in t

66 he proportion of subjects with pharmacologic VMA resolution at day 28.

67 A with 90-94% [mm], while the polymerization VMA is least stereospecific.

68 the baseline visit to identify the presence (VMA+) or absence (VMA-) of VMA.

69 (intein) from Saccharomyces cerevisiae (Sce VMA intein) in conjunction with a chitin-binding domain

70 sed on the observation that the modified Sce VMA intein can be induced to undergo a self-cleavage rea

71 1 intein switches, temperature-sensitive Sce VMA mutations that splice only at the permissive tempera

72 hat the N- and C-terminal regions of the Sce VMA intein may form a separate domain that is not only c

73 e have recently reported an engineered split VMA intein whose splicing activity in trans between two

74 aromyces cerevisiae vacuolar ATPase subunit (VMA) intein inserted within Gal4 and transferred these i

75 ent (intein) of the vacuolar ATPase subunit (VMA) of Saccharomyces cerevisiae catalyzes both protein

76 g the intein of the vacuolar ATPase subunit (VMA) of Saccharomyces cerevisiae that involves cysteines

77 ient-reported visual function in symptomatic VMA/vitreomacular traction (VMT) has not yet been docume

78 ient-reported visual function in symptomatic VMA/VMT.

79 providing improved resolution of symptomatic VMA compared with previous phase 3 trials with no additi

80 Patients with symptomatic VMA/VMT were randomly assigned (2:1 or 3:1 in study TG-M

81 A total of 652 patients with symptomatic VMA/VMT, including when associated with a macular hole 4

82 The results of this study suggest that VMA might be a consequence rather than a causative facto

83 The VMA intein, which encodes the PI-SceI endonuclease in Sa

84 degrees at VMT, compared to the angle at the VMA stage.

85 11.31+/-6.67 and 6.86+/-7.58 letters in the VMA+ and VMA- groups, respectively (P = 0.007).

86 .81+/-132.31 and -161.84+/-131.34 mum in the VMA+ and VMA- groups, respectively (P = 0.681).

87 Urinary VMA excretion, serum FGF23, and renal phosphate and calc

88 llow-up (n = 60), 13.8 +/- 0.7 for eyes with VMA at baseline or follow-up (n = 79), and 12.9 +/- 0.4

89 Eyes with VMA were classified according to the diameter of vitreou

90 The safety of ocriplasmin in patients with VMA and wet AMD was shown to be comparable to the known

91 A total of 100 patients with VMA and wet AMD were randomized 3:1 to receive 125 mug o

92 Diabetic macular edema patients with VMA have a greater potential for improvement in visual o

93 nd point was the proportion of patients with VMA release at day 28 after injection.

94 novo CNV development in eyes with or without VMA.